These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 31208414)

  • 21. Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.
    Hansen BC; Tigno XT; Bénardeau A; Meyer M; Sebokova E; Mizrahi J
    Cardiovasc Diabetol; 2011 Jan; 10():7. PubMed ID: 21251281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control.
    Bays HE; Brinton EA; Triscari J; Chen E; Maccubbin D; MacLean AA; Gibson KL; Ruck RA; Johnson-Levonas AO; O'Neill EA; Mitchel YB
    Vasc Health Risk Manag; 2015; 11():165-72. PubMed ID: 25750540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical evaluation of saroglitazar magnesium, a dual PPAR-α/γ agonist for treatment of dyslipidemia and metabolic disorders.
    Patel H; Giri P; Patel P; Singh S; Gupta L; Patel U; Modi N; Shah K; Jain MR; Srinivas NR; Patel P
    Xenobiotica; 2018 Dec; 48(12):1268-1277. PubMed ID: 29224415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of dual PPAR-α/γ agonist saroglitazar on diabetic retinopathy and oxygen-induced retinopathy.
    Joharapurkar A; Patel V; Kshirsagar S; Patel MS; Savsani H; Jain M
    Eur J Pharmacol; 2021 May; 899():174032. PubMed ID: 33753107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized study.
    Ruilope L; Hanefeld M; Lincoff AM; Viberti G; Meyer-Reigner S; Mudie N; Wieczorek Kirk D; Malmberg K; Herz M
    BMC Nephrol; 2014 Nov; 15():180. PubMed ID: 25407798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
    Jain MR; Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Ranvir R; Kadam S; Patel H; Swain P; Roy SS; Das N; Karmakar E; Wahli W; Patel PR
    Liver Int; 2018 Jun; 38(6):1084-1094. PubMed ID: 29164820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiovascular Risk and Safety Evaluation of a Dual Peroxisome Proliferator-Activated Receptor-Alpha/Gamma Agonist, Aleglitazar, in Patients With Type 2 Diabetes: A Meta-analysis.
    Han CL; Qu CZ
    J Cardiovasc Pharmacol; 2020 Apr; 75(4):351-357. PubMed ID: 31929323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control.
    Bloomgarden Z
    J Diabetes; 2017 Aug; 9(8):722-723. PubMed ID: 28513098
    [No Abstract]   [Full Text] [Related]  

  • 31. Study of Saroglitazar in Treatment Of Pre-diabetes with Dyslipidemia: STOP-D.
    Bhosle D; Bhosle V; Bobde J; Bhagat A; Shaikh H; Kadam R
    J Assoc Physicians India; 2018 Mar; 66(3):14-7. PubMed ID: 30341861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Food on the Pharmacokinetics of Saroglitazar Magnesium, a Novel Dual PPARαγ Agonist, in Healthy Adult Subjects.
    Patel MR; Kansagra KA; Parikh DP; Parmar DV; Patel HB; Soni MM; Patil US; Patel HV; Patel JA; Gujarathi SS; Parmar KV; Srinivas NR
    Clin Drug Investig; 2018 Jan; 38(1):57-65. PubMed ID: 29022212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.
    Wilding JP; Gause-Nilsson I; Persson A;
    Diab Vasc Dis Res; 2007 Sep; 4(3):194-203. PubMed ID: 17907109
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes.
    Ratner RE; Parikh S; Tou C;
    Diab Vasc Dis Res; 2007 Sep; 4(3):214-21. PubMed ID: 17907111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Nowrouzi-Sohrabi P; Rezaei S; Jalali M; Ashourpour M; Ahmadipour A; Keshavarz P; Akbari H
    Eur J Pharmacol; 2021 Feb; 893():173823. PubMed ID: 33352183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saroglitazar and Hepano treatment offers protection against high fat high fructose diet induced obesity, insulin resistance and steatosis by modulating various class of hepatic and circulating lipids.
    Sarkar S; Kumari D; Gupta SK; Sharma V; Mukhi S; Kamboj P; Sasibhushan V; Rai RK; Jatavallabhula SL; Mahajan D; Kumar Y; Kumar A; Dikshit M
    Biomed Pharmacother; 2021 Dec; 144():112357. PubMed ID: 34794234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial.
    Rodriguez-Gutierrez R; González JG; Parmar D; Shaikh F; Cruz-López P
    J Lipid Res; 2022 Jul; 63(7):100233. PubMed ID: 35605678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Examining the safety of PPAR agonists - current trends and future prospects.
    Bortolini M; Wright MB; Bopst M; Balas B
    Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease.
    Goyal P; Goyal O; Chhina RS
    J Assoc Physicians India; 2020 Jan; 68(1):97. PubMed ID: 31979903
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.